The present invention relates to a composition for preventing and treating liver fibrosis or cirrhosis and, more specifically, to a pharmaceutical composition for preventing and treating liver fibrosis or cirrhosis, comprising an expression or activity enhancer of transcriptional intermediary factor 1 gamma (TIF1γ) as an active ingredient, and a method for screening the same. The pharmaceutical composition for preventing or treating liver fibrosis or cirrhosis, comprising an expression or activity enhancer of TIF1γ as an active ingredient, according to the present invention, inhibits the activity of hepatic stellate cells (HSCs) and decreases the expression of α-SMA proteins or the secretion of collagen Type I, thereby ultimately being expected to be developed as a prophylactic or therapeutic agent for liver fibrosis or cirrhosis. In addition, the composition of the present invention is expected to be useful in a method for screening an agent for liver fibrosis or cirrhosis.
